Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up specializing in Adaptive Laboratory Evolution (ALE). Created in 2017, Altar will complement Lesaffre’s existing know-how […]
dsm-firmenich, innovators in nutrition, health and beauty, today announces the completion of the sale of its yeast extract business to Lesaffre, a global player in fermentation and microorganisms. The sale of the yeast extract business […]
Ostia Sciences Inc., a spinout from the University of Toronto specializing in oral and respiratory microbiome solutions, has successfully raised over CAD $1 million in its seed round and secured full intellectual property (IP) transfer […]
Florey Biosciences, a synthetic biology company spun out of the Wyss Institute for Biologically Inspired Engineering at Harvard University, today announced that it has secured pre-seed funding and is unveiling its lead program, a probiotic […]
Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, announced the closing of a €35 million financing round led by an international consortium of investors. This funding will fuel the company’s expansion into global […]
32 Biosciences, pronounced “Three Squared Biosciences,” announces its emergence from stealth mode, with new microbiome diagnostic management tools and microbiome-based interventions. The company intends to revolutionize healthcare with its novel approach to gut microbiome medicine. […]
Viome, a pioneer in microbiome health science and personalized health solutions, today announced a $25 million internal Series D with participation from Khosla Ventures, Bold Capital WRG Ventures, Marc Benioff, and more. This continued support from existing backers […]
Lallemand announces the inauguration of its new laboratories in France, increasing its capacity by over 800 square meters. This significant expansion enhances its interdisciplinary research and development capabilities at the Blagnac and Beauzelle sites. The […]
Infant Bacterial Therapeutics has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company’s drug candidate IBP-9414, a bacterial strain found […]
ZBiotics, the pioneers carving a new category of genetically engineered probiotics, today announced the close of its $12M Series A funding round, led by Spring Tide Capital. The oversubscribed round also includes participation by Access Capital, Seamless Capital, Goat […]
Choosing the right CDMO partner is one of the hardest steps a CEO must undertake when embarking on their drug development journey. The CEO must consider the quality, experience, and cost of a prospective partner, […]